Literature DB >> 11861425

PPARgamma ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells.

Yuko Oyama1, Nobuhiro Akuzawa, Ryozo Nagai, Masahiko Kurabayashi.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the nuclear receptor superfamily that acts as a key player in adipocyte differentiation, glucose metabolism, and macrophage differentiation. Osteopontin (OPN), a component of extracellular matrix, is elevated during neointimal formation in the vessel wall and is synthesized by macrophages in atherosclerotic plaques. In the present study, we investigated the molecular mechanisms regulating OPN gene expression by PPARgamma in THP-1 cells, a cell line derived from human monocytic leukemia cells. Northern and Western blot analyses showed that exposure of THP-1 cells to PMA (phorbol 12-myristate 13-acetate) increases OPN mRNA and protein levels in a time-dependent manner. PMA-induced OPN expression was significantly decreased by troglitazone (Tro) and other PPARgamma ligands. Transient transfection assays of the human OPN promoter/luciferase construct showed that PPARgamma represses OPN promoter activity, and the PPARgamma-responsive region within the OPN promoter lies between -1000 and -970 relative to the transcription start site. Site-specific mutation analysis and electrophoretic mobility shift assays indicated that a homeobox-like A/T-rich sequence between -990 and -981, which functions as a binding site for PMA-induced nuclear factors other than PPARgamma, mediates the repression of OPN expression by Tro. Furthermore, concatenated A/T-rich sequences conferred the PPARgamma responsiveness on the heterologous promoter. Taken together, these data suggest that PPARgamma ligand inhibits OPN gene expression through the interference with the binding of nuclear factors to A/T-rich sequence in THP-1 cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861425     DOI: 10.1161/hh0302.105098

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  21 in total

1.  Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damage.

Authors:  Eva Kiss; Zoran V Popovic; Jens Bedke; Judith Adams; Mahnaz Bonrouhi; Andrea Babelova; Claudia Schmidt; Frank Edenhofer; Inka Zschiedrich; Sophie Domhan; Amir Abdollahi; Liliana Schäfer; Norbert Gretz; Stefan Porubsky; Hermann-Josef Gröne
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

2.  Elevated myocardial Na+/H+ exchanger isoform 1 activity elicits gene expression that leads to cardiac hypertrophy.

Authors:  Jin Xue; Fatima Mraiche; Dan Zhou; Morris Karmazyn; Tatsujiro Oka; Larry Fliegel; Gabriel G Haddad
Journal:  Physiol Genomics       Date:  2010-05-11       Impact factor: 3.107

3.  Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice.

Authors:  Takashi Nomiyama; Diego Perez-Tilve; Daisuke Ogawa; Florence Gizard; Yue Zhao; Elizabeth B Heywood; Karrie L Jones; Ryuzo Kawamori; Lisa A Cassis; Matthias H Tschöp; Dennis Bruemmer
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

4.  Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle.

Authors:  Christopher J Pelham; Henry L Keen; Steven R Lentz; Curt D Sigmund
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-02-27       Impact factor: 3.619

Review 5.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.

Authors:  Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

6.  Peroxisome proliferator-activated receptor gamma ligands inhibit cell growth and induce apoptosis in human liver cancer BEL-7402 cells.

Authors:  Ming-Yi Li; Hua Deng; Jia-Ming Zhao; Dong Dai; Xiao-Yu Tan
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

7.  Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.

Authors:  Arnica Behringer; Manuela Trappiel; Eva Maria Berghausen; Henrik Ten Freyhaus; Ernst Wellnhofer; Margarete Odenthal; Florian Blaschke; Fikret Er; Natig Gassanov; Stephan Rosenkranz; Stephan Baldus; Kai Kappert; Evren Caglayan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-01-07       Impact factor: 3.000

8.  Osteopontin is increased in HIV-associated dementia.

Authors:  Tricia H Burdo; Ronald J Ellis; Howard S Fox
Journal:  J Infect Dis       Date:  2008-09-01       Impact factor: 5.226

9.  Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity.

Authors:  Adeline Bertola; Vanessa Deveaux; Stéphanie Bonnafous; Déborah Rousseau; Rodolphe Anty; Abdelilah Wakkach; Moncef Dahman; Joan Tordjman; Karine Clément; Siobhán E McQuaid; Keith N Frayn; Pierre-Michel Huet; Jean Gugenheim; Sophie Lotersztajn; Yannick Le Marchand-Brustel; Albert Tran; Philippe Gual
Journal:  Diabetes       Date:  2008-10-24       Impact factor: 9.461

10.  Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice.

Authors:  Adrienn Kis; Colin Murdoch; Min Zhang; Anjana Siva; Sergio Rodriguez-Cuenca; Stefania Carobbio; Agnes Lukasik; Margaret Blount; Steve O'Rahilly; Sarah L Gray; Ajay M Shah; Antonio Vidal-Puig
Journal:  Eur J Heart Fail       Date:  2009-04-24       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.